SG11201810358YA - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- methods
- pct
- negative symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034030 WO2017205393A1 (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810358YA true SG11201810358YA (en) | 2018-12-28 |
Family
ID=58794265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3463356A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019516756A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190013846A (cg-RX-API-DMAC7.html) |
| CN (3) | CN113908156A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12018502445A1 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201810358YA (cg-RX-API-DMAC7.html) |
| TW (2) | TWI851224B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017205393A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458130B2 (en) | 2014-12-02 | 2016-10-04 | Minerva Neurosciences, Inc. | Compositions and methods for treating schizophrenia |
| US11464744B2 (en) | 2017-06-21 | 2022-10-11 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MX2021002017A (es) * | 2018-08-21 | 2021-04-28 | Minerva Neurosciences Inc | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. |
| TWI879755B (zh) * | 2020-02-20 | 2025-04-11 | 日商田邊三菱製藥股份有限公司 | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 |
| KR102360137B1 (ko) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | 카트리지 및 이를 포함하는 에어로졸 생성 장치 |
| US11957675B2 (en) * | 2021-02-09 | 2024-04-16 | Xenon Pharmaceuticals Inc. | Methods and uses for treating anhedonia |
| US20240212824A1 (en) * | 2022-12-21 | 2024-06-27 | Woebot Labs, Inc. | Administering a digital therapeutic using a device interface to treat anxiety or depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0300203A3 (en) * | 2000-02-29 | 2006-01-30 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives, and pharmaceutical compositions containing same |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| KR20080093453A (ko) * | 2006-02-07 | 2008-10-21 | 미쓰비시 타나베 파마 코퍼레이션 | 4-아실아미노피리딘 유도체 매개된 신경조직발생 |
| KR20080089279A (ko) * | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| KR101867633B1 (ko) * | 2010-07-20 | 2018-06-15 | 미쓰비시 타나베 파마 코퍼레이션 | 정신분열증을 치료하기 위한 시클릭 아미드 유도체의 사용 방법 |
| CA2805904C (en) * | 2010-07-20 | 2022-06-21 | Cyrenaic Pharmaceuticals, Inc. | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2015174534A1 (ja) * | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US9458130B2 (en) * | 2014-12-02 | 2016-10-04 | Minerva Neurosciences, Inc. | Compositions and methods for treating schizophrenia |
-
2017
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en not_active Ceased
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/zh active Pending
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en not_active Withdrawn
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/ja active Pending
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/ko not_active Ceased
- 2017-05-23 TW TW112118953A patent/TWI851224B/zh active
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/ko not_active Ceased
- 2017-05-23 TW TW106117023A patent/TWI820001B/zh active
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/zh active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/zh active Pending
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en not_active Abandoned
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173054A patent/JP2025000921A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI820001B (zh) | 2023-11-01 |
| CN109689055A (zh) | 2019-04-26 |
| TW202335672A (zh) | 2023-09-16 |
| SG10202011470UA (en) | 2021-01-28 |
| US20230190726A1 (en) | 2023-06-22 |
| CN113908156A (zh) | 2022-01-11 |
| PH12018502445A1 (en) | 2019-09-09 |
| WO2017205393A1 (en) | 2017-11-30 |
| US20190216793A1 (en) | 2019-07-18 |
| CN113694065A (zh) | 2021-11-26 |
| TWI851224B (zh) | 2024-08-01 |
| JP2019516756A (ja) | 2019-06-20 |
| EP3463356A1 (en) | 2019-04-10 |
| TW201808288A (zh) | 2018-03-16 |
| JP2025000921A (ja) | 2025-01-07 |
| KR20240005110A (ko) | 2024-01-11 |
| JP2022188185A (ja) | 2022-12-20 |
| KR20190013846A (ko) | 2019-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810358YA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |